The clinical benefit of the decrease in opioid consumption has not been demonstrated.
EXPAREL is indicated for single-dose administration into the surgical site to produce postsurgical analgesia.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use
in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may
cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration
of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations
of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of
cardiovascular and neurological status, as well as vital signs should be performed during and after injection of
EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine,
are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with
severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk
of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence ≥10%)
following EXPAREL administration were nausea, constipation, and vomiting. Studies demonstrating the safety
and efficacy of EXPAREL were conducted in hemorrhoidectomy and bunionectomy; EXPAREL has not been
demonstrated to be safe and effective in other procedures.
Please see brief summary of Prescribing Information on reverse side.
For more information, please visit www.EXPAREL.com or call 1-855-RX-EXPAREL (793-9727).
Data on file. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; February 2015.
Used in more than
1 MILLION PATIENTS since 2012
Experience the impact:
Reduce the need for opioids while providing long-lasting
postsurgical pain control—all from a single dose.
With EXPAREL, we are
able to deliver pain relief
without catheters or pumps, and
our opioid use has greatly decreased.
— Stephan J. Finical, MD
Charlotte, North Carolina